Key Points
- Insider sale: InspireMD insider Shane Thomas Gleason sold 3,858 shares at an average price of $2.71, worth about $10,455. The filing says the sale was to cover tax withholding tied to vesting equity awards.
- Stock and trading context: NSPR shares were up 3.0% to $1.03, but the stock remains near its 12-month low of $0.97 and well below its 50-day and 200-day moving averages. InspireMD has a market cap of about $48.24 million.
- Sentiment and outlook: Analysts remain broadly bullish, with three Buy ratings and a consensus price target of $4.50. However, repeated insider selling and weak recent price action continue to weigh on investor sentiment.
InspireMD, Inc. (NYSE:NSPR - Get Free Report) insider Shane Thomas Gleason sold 3,858 shares of the stock in a transaction on Monday, January 27th. The stock was sold at an average price of $2.71, for a total value of $10,455.18. Following the completion of the transaction, the insider directly owned 1,135,319 shares in the company, valued at $3,076,714.49. This trade represents a 0.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Shane Thomas Gleason also recently made the following trade(s):
- On Tuesday, May 19th, Shane Thomas Gleason sold 22,778 shares of InspireMD stock. The stock was sold at an average price of $1.01, for a total value of $23,005.78.
InspireMD Trading Up 3.0%
Shares of NSPR opened at $1.03 on Friday. The firm has a market capitalization of $48.24 million, a P/E ratio of -1.37 and a beta of 0.82. The stock's fifty day simple moving average is $1.39 and its 200 day simple moving average is $1.67. InspireMD, Inc. has a twelve month low of $0.97 and a twelve month high of $2.93.
InspireMD News Roundup
Here are the key news stories impacting InspireMD this week:
- Positive Sentiment: There were no clearly positive company-specific announcements in the latest items, so investor attention is centered on the stock’s low valuation and recent trading near its 1-year low. InspireMD (NSPR) Stock Forecast & Price Target
- Neutral Sentiment: The most recent insider sale was small and attributed to tax withholding obligations tied to equity award vesting, which often makes the transactions less concerning than open-market selling. Multiple similar sales were also reported earlier this year. SEC filing
- Negative Sentiment: Repeated insider sales can still weigh on sentiment, as investors may view them as a sign of limited near-term upside or a lack of conviction from management, especially for a small-cap stock already trading below its recent moving averages. SEC filing
Hedge Funds Weigh In On InspireMD
A number of hedge funds have recently bought and sold shares of the company. Raymond James Financial Inc. grew its stake in InspireMD by 28.9% in the second quarter. Raymond James Financial Inc. now owns 44,604 shares of the company's stock worth $101,000 after purchasing an additional 10,000 shares in the last quarter. Citadel Advisors LLC boosted its stake in InspireMD by 45.0% in the third quarter. Citadel Advisors LLC now owns 37,954 shares of the company's stock valued at $91,000 after acquiring an additional 11,778 shares during the period. Rosalind Advisors Inc. boosted its stake in InspireMD by 0.6% in the second quarter. Rosalind Advisors Inc. now owns 2,289,099 shares of the company's stock valued at $5,196,000 after acquiring an additional 14,109 shares during the period. XTX Topco Ltd acquired a new position in InspireMD in the fourth quarter valued at approximately $30,000. Finally, Renaissance Technologies LLC acquired a new position in InspireMD in the first quarter valued at approximately $29,000. 44.78% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
NSPR has been the topic of several research reports. Lake Street Capital set a $4.00 target price on InspireMD in a research report on Monday, May 4th. Loop Capital set a $5.00 price objective on InspireMD in a research report on Tuesday, February 24th. Maxim Group began coverage on InspireMD in a research report on Monday, February 2nd. They issued a "buy" rating and a $6.00 price objective on the stock. Finally, Piper Sandler reissued an "overweight" rating and issued a $3.00 price objective (down from $4.00) on shares of InspireMD in a research report on Tuesday, May 5th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $4.50.
Check Out Our Latest Stock Analysis on InspireMD
InspireMD Company Profile
(
Get Free Report)
InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company's core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.
The company's flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
